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ABSTRACT 
 
Surgical site infection (SSI) is a devastating outcome of lumbar fusion surgery arising in 
8.5% of primary procedures. This infection is often marked by the formation of biofilm, 
which is highly resistant to antibiotics, thus the only treatment for SSI is secondary 
surgery. Ultrasound has been recently found to mechanically disrupt biofilm, increasing 
its antibiotic susceptibility, and is often used to trigger drug release. In this study, an 
ultrasound-triggered antibiotic release device has been developed. The device is made of 
selective laser sintered polyetheretherketone (PEEK) and clips to a standard 5.5 mm 
lumbar fusion rod. Initially, the clip will be loaded with antibiotic and sealed with a 
poly(lactic acid) (PLA) membrane, however, with application of ultrasound, the 
membrane will rupture, releasing antibiotic directly into the surgical site. Dimensional 
accuracy was verified using computer tomography and the SLS PEEK material was 
found to be 38% porous. A model was developed to understand the mechanism of release 
from the clip. The model supported the hypothesis that release occurred through the walls 
of the clip as well as from the drug delivery channel, highlighting the necessity of a 
robust membrane to retain drug. The membrane was applied via submersion in a PLA-
chloroform solution. The amount of PLA deposited on the clip was varied by changing 
the number of dips and the concentration of PLA. To assess membrane drug retention and 
responsiveness to ultrasound-triggered release, clips were incubated for 7 days in 
physiological conditions, then sonicated at day 7. The high concentration membrane 
showed the greatest retention, retaining 81% of the loaded drug over 7 days, however, it 
was unperturbed by ultrasound. The low concentration clips only retained 62% of their 
drug, but showed an increase in release rate after ultrasound. Further investigation should 
	   	   xi	   	   	  
	  
focus on membrane optimization: finding the precise number of dips and PLA 
concentration to fulfill the design criteria. The next step would then be to assess the 
antibacterial effectiveness of the device. This study has demonstrated promising initial 
feasibility of the drug delivery clip. With further development, this device could be 
implemented with current clinical antibiotic prophylaxis, to provide another layer of 
protection. This staged treatment with antibiotics could further reduce the incidence of 
surgical site infection, decreasing health care costs, disability of this serious 
complication. 
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1. INTRODUCTION 
 
 
1.1 Lumbar Spinal Fusion Surgery 
 
Lumbar posterior fusion surgery (LPFS) is a procedure used to restore mechanical 
stability to the lumbar region of the spine [1]. While the technique and instrumentation 
have changed since the procedure was first described by Albee and Hibb in 1911, the 
primary goal of the surgery has remained constant: to achieve bony fusion of the 
vertebral discs [2]. It is considered the gold standard in the treatment of congenital 
scoliosis and spinal collapse following tumor resection, infection, or trauma [1]. 
However, these indications account for only 25% of LPFS procedures performed in the 
United States [3]. The other 75% of procedures are prompted by intractable pain due to  
degenerative changes in the spine, such as disc herniation, stenosis, and disc migration [3, 
4]. Despite debate in the field over the effectiveness of LPFS in treating these 
degenerative conditions, the rate of LPFS increased 220% between 1990 and 2005 [5, 6]. 
The average cost of a single procedure is $34,000, and in 2008, the total bill for all spinal 
surgeries performed in the United States was $33.9 billion [6]. 
 
The most common approach to LPFS is postereolateral fusion (also known as bilateral-
lateral fusion, lateral mass fusion, and transverse process fusion), in which, an incision is 
made down the midline of the spinal column [1]. The degenerated intervertebral disc is 
then dissected and the space is filled with either autologous bone from the patient’s iliac 
crest, a synthetic bone matrix, or an inter-body fusion device [1]. Regardless of type, 
	   	   	   	   	  
	  
2
these fillers are meant to promote osseoinduction of the neighboring vertebrae leading to 
fusion and long-term stability [1].  
 
As bony fusion takes many months to achieve mechanical stability, rigid internal fixation 
has been implemented to provide perioperative stability to the joint. Pedicle screws are 
anchored into vertebral disks and titanium rods that mimic the curvature of the spine are 
threaded through the screws, stabilizing them (Figure 1) [2]. 
 
 
 
 
Figure 1: Rigid internal fixation device, retrieval courtesy of the Implant Research Center 
(Drexel University). The titanium rod mimics the curvature of the lumbar spine and is 
anchored to the vertebrae via the pedicle screws, providing immediate stability to the 
spine. 
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While there are concerns that the rigid fixation devices induce stress shielding, thereby 
limiting vertebral fusion, studies have shown an 86% fusion rate in rigid fixation versus 
64% fusion rate without [1]. 
 
1.2 Infection in Spinal Fusion Surgery 
 
Surgical Site Infection (SSI) arises in 8.5% of primary and 12.2 % of revision LPFS 
procedures according to a 2011 retrospective analysis of Medicare data [7]. Clinical 
presentation usually involves purulent drainage from the wound site, fever, and localized 
redness and tenderness [8]. Diagnosis may be confirmed by collecting a local culture and 
analyzing blood for increased levels of neutrophils and C-reactive proteins [9].  Gram 
positive bacteria, such as S. aureus and S. epidermidis, are most commonly implicated in 
SSI in LPFS [10]. However, gram negative bacteria, such as E. coli and Enterococcus, 
are also seen in 30% of SSI cases [10].  
 
Treatment needs to be administered promptly after diagnosis, and must balance the need 
to maintain spinal stability with the necessity to resolve the infection [11]. A large dose 
of systemic antibiotics is the first step and aggressive surgical wound debridement is 
performed to clean the wound of bacteria [12]. In extreme cases, hardware replacement is 
indicated if the instrumentation is completely fouled with bacteria [12]. The average cost 
of treating SSI is between $15,800 and $43,900, essentially doubling the cost of the 
initial LPFS procedure and extending patient hospitalization and suffering [10]. 
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Moreover, patients with major perioperative device complications (including SSI) report 
higher rates of pain and continued long-term disability [13]. 
 
1.3 Biofilm Infections 
 
SSI is often marked by the formation of bacterial biofilm, which ensures that bacteria are 
recalcitrant to antibiotic treatment and are able to subvert immune surveillance, allowing 
establishment of persistent infections. While the development of biofilm consists of 
hundreds of complex steps, there is general agreement that progression can be 
summarized in four major steps. Stage 1 of development is abiotic. Immediately upon 
implantation, the device surface is decorated with adsorbed water, albumin, lipids, and 
extracellular matrix (ECM) proteins [14]. This coated surface is ideal for adherence of 
bacterial contaminants (mostly from the air of the operating room), reversibly binding via 
intermolecular interactions in stage 2 of biofilm development [15]. Within hours stage 3 
occurs, where these bacteria proliferate and begin producing a hydrated matrix of 
glycoproteins, called the glycocalax [16]. The basal layer of bacteria irreversibly bind 
using adhesion proteins, anchoring the biofim to the implant surface [14]. When the 
biofilm reaches its final stage of maturity, cells on the outer surface break off, reverting 
back to their planktonic phenotype [15]. These cells can circulate to other sites within the 
host, causing a chronic and systemic infection [17]. The stages of biofilm development 
are illustrated in figure 2.  
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Figure 2: Proteins adsorb to and decorate the surface of an implanted device. Planktonic 
bacteria (green) colonize the surface and begin proliferating. Through quorum sensing, 
the bacteria change to the sessile phenotype (pink) and secrete a glycocalyx matrix 
(purple). Bacteria near the surface of the biofilm detach and revert back to their 
planktonic state, causing a chronic infection. 
 
 
Bacteria within the biofilm develop a multi-modal tolerance to antimicrobial agents. Cells 
deep within the biofilm are insulated from the external environment by layers of 
glycocalyx, hindering antimicrobial penetration [18]. Moreover, bacteria within the 
matrix change phenotype, from a planktonic state to a sessile state [15]. This is due to a 
change in gene expression induced through intercellular quorum sensing [19]. In their 
sessile state, bacterial metabolism and proliferation slows; and expression of genes 
related to multidrug resistance increases [20]. In combination, these conditions make 
biofilms extremely recalcitrant to antimicrobial therapy. While the minimum inhibitory 
concentration of vancomycin (VAN) for planktonic S. aureus is 2 μg/mL, the minimum 
biofilm eradication concentration is reported to be 64-512 times higher [21, 22, 23]. 
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1.4 Prophylactic Techniques to Combat SSI 
 
Due to the persistence and devastation of bacterial biofilm, the primary goal in 
combatting SSI in LPFS is prophylaxis. Before and after surgery, systemic antibiotics 
such as ampicillin are administered [24]. Advanced sterile surgical techniques are 
employed to minimize bacterial exposure in the operating room. This includes the use of 
autoclaved surgical instruments, sterile draping, and the maintenance of a sterile field of 
operation [9]. At the end of the implantation procedure, the wound is often packed with 
up to one gram of powdered vancomycin, which is meant to kill any bacteria which have 
entered the wound during surgery [25]. This has shown promising results: in one clinical 
retrospective study of 1,512 patients only 0.99% presented with infection during the 5 
year study period [26]. Vacuum assisted wound closure may also be applied for one to 
two days post-surgery to drain edematous fluid and increase blood flow to the local 
region [27, 28]. While these suture drains are generally accepted in the field as beneficial 
for wound healing and the formation of new granulation tissue, they may conflict with 
antibiotic wound packing since much of the VAN packed in the wound site may evacuate 
through the drains, attenuating antimicrobial potential. Despite this aggressive antibiotic 
prophylaxis, SSI in LPFS continues to persist. 
 
Current anti-infection biomaterials research can be broadly separated into two categories: 
passive surface layers that inhibit initial bacterial colonization and active surface layers 
that release an antimicrobial agent [29]. Silver is a popular passive surface layer that can 
be applied efficiently and homogeneously via ion surface deposition [30]. Silver prevents 
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a broad spectrum of bacteria from proliferating on an implant surface and can be 
functionalized with antibacterial peptides such as polymyxin B to further increase biofilm 
inhibition [31]. Another passive layer approach is to covalently attach poly(sulfobetaine 
methacrylate), creating a zwitterionic surface that inhibits protein adsorption and 
bacterial adhesion [32]. The primary benefit of these passive coatings is that they are 
generally stable and permanent, inhibiting bacterial attachment long after the 
perioperative period. They also do not come with a high risk of antibacterial resistance. 
However, they can be scratched or damaged during implantation, diminishing their 
effectiveness. 
 
A common active coating is isopentyl nitrite, which releases nitric oxide, an effective 
bactericidal agent. In a 2015 study, inhibition of S. epidermidis growth was achieved over 
a 14 hour period using this approach [33]. Cationic antimicrobial steroid 13 was also 
mixed into a PDMS coating and deposited on the surface of a stainless steel plate, 
showing biofilm inhibition of P. aeruginosa over a 24 hour period [34]. Finally, PLGA 
microbubbles loaded with triclosan and deposited on titanium surfaces have shown 
degradation-controlled release over 80 hours [35]. While these coatings have all shown 
excellent antibacterial effect, they are limited in that their release cannot be temporally-
controlled. Antibiotic release begins at implantation and is depleted within, at most, one 
week of the surgery. While the perioperative period is the most critical time for 
antimicrobial therapy, long-term infection mitigation cannot be achieved using these 
approaches. 
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1.5 Ultrasound-Disruption of Bacterial Biofilm 
 
In light of bacterial biofilm recalcitrance to antibiotic therapies, many techniques are 
currently under investigation to disrupt biofilms and enhance their susceptibility to 
antibiotics. Recently, it has been shown that low-intensity ultrasound is disruptive to 
biofilms and enhances both sessile and planktonic bacterial antibiotic susceptibility. One 
in vitro study showed that by treating S. epidermitis biofilm with VAN (100 μg/mL) and 
US, a significant increase in bacterial death could be achieved relative to antibiotic 
treatment alone [36]. The treatment was further enhanced by the addition of 
microbubbles, which burst in response to ultrasound, mechanically altering the biofilm 
surface [36]. These results have been confirmed in vitro and a similar effect has been 
observed on implanted polyethylene disks and antibiotic eluting bone cement in rabbits in 
vivo [36, 37, 38]. More promising still, one study has shown an increase in human 
neutrophil bactericidal activity stimulated by ultrasound [39]. This study demonstrated 
enhanced neutrophil infiltration into a fibrin gel challenged with S. epidermidis, mediated 
by surface integrin CD18 [39]. While a somewhat new approach to the treatment of 
biofilm infections, ultrasound has demonstrated promising enhancement to biofilm 
antibiotic susceptibility. 
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Figure 3: Summary of prophylactic antimicrobial practices and their intervention within 
the development of a biofilm. Black points are current clinical practices and red points 
are surface coatings under investigation. 
 
 
2. DEVICE DESIGN 
 
 
2.1 Problem Definition 
 
Surgical Site Infection (SSI) is a devastating outcome of lumbar spinal fusion surgery 
(LPFS), arising in 8.5% of primary and 12% of revision procedures [7]. SSI is often the 
result of biofilm formation on the implant surface, in which the bacteria create a 
protective gelatinous matrix of proteoglycans [16]. In this state, bacteria are extremely 
difficult to eradicate with systemic antibiotics and treatment is limited to secondary 
surgery—either aggressive debridement and irrigation of the wound or removal of current 
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device in extreme cases [12]. This secondary surgery prolongs patient suffering, extends 
hospital stay, increases mortality and can easily double the cost of the original LPFS 
procedure [10]. 
 
 
2.2 Design Rationale 
 
The goal in treating SSI must be prophylaxis. By preventing bacteria from developing 
into a biofilm, infection and the associated secondary surgery may be avoided. There is 
currently a multi-stage regimen of clinical practices aimed at preventing bacterial 
attachment and biofilm maturation (Figure 3). Despite these clinical practices, the 
incidence of infection persists so that there is an urgent need to develop further 
antimicrobial technology. Current biomaterials research is focused on surface coatings 
that prevent bacterial attachment, but no research is focused on eradicating bacteria that 
persist despite these defenses and begin forming biofilm. Such a contingency would add 
one more barrier for bacteria to overcome in the development of a biofilm and thus would 
reduce incidence of SSI. In this study we will develop a drug-filled clip for ultrasound-
triggered release of antibiotics to the LPFS surgical site one week after implantation. Not 
only will a supra-therapeutic dose of antibiotic be delivered to the surgical site, but 
ultrasound has been shown to enhance biofilm antibiotic susceptibility (Figure 4). This 
two-pronged attack should eradicate any remaining bacteria in the surgical site that would 
have the potential to develop into surgical site infection. 
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Figure 4: The device is a clip (tan) that can engage with a spinal fusion rod. (A) With the 
application of ultrasound, a supra-therapeutic dose of antibiotic is released directly into 
the wound site. (B) Ultrasound will disrupt the bacterial biofilm on the implant surface 
and enhance both sessile (pink) and planktonic (green) bacterial susceptibility to the 
antibiotic.  
 
 
2.3 Design Overview 
 
The device is a clip, manufactured in selective laser sintered (SLS) polyetheretherketone 
(PEEK) that attaches to a standard 5.5 mm lumbar spinal fusion rod. The clip houses a 
reservoir containing a dose of powdered antibiotic. While the precise dose will ultimately 
depend on the density of selected antibiotic, we have found the clip can hold 120 mg of 
methylene blue, which is a dye whose solubility and density are similar to vancomycin, a 
widely-used antibiotic. A key strength of this device is that multiple antibiotics can be 
loaded into the reservoir to eradicate a broad range of bacterial species. The drug will be 
sealed within the clip by a hydrophobic poly(lactic acid) membrane. 
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Figure 5: The SLS PEEK clip will attach to a spinal fusion rod at the time of surgery, 
initially containing a dose of antibiotic. The antibiotic is contained within a poly(lactic 
acid) membrane, which will rupture in response to an ultrasound trigger. 
 
 
 
 
The device will be initially clipped onto the spinal fusion rod at the time of surgery. 
During the first week following implantation, the clip will remain inactive in the wound 
site, simply retaining the antibiotic. Approximately one week post-implantation, 
ultrasound will be applied to the wound site, which will rupture the PLA membrane and 
release antibiotic into the surgical site. 
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2.4 Design Criteria 
 
1. Clip to a standard 5.5 mm spinal fusion rod without impeding the primary 
function of the device. 
The primary function of a spinal fusion rod is to stabilize the spinal column and 
promote boney fusion between vertebrae. Pedicle screws, attached to the rod, are 
drilled into the vertebral disks, anchoring them in place. The clip will attach to 
the rod in between pedicle screws. Careful consideration must be made when 
designing the device so that the clip does not impinge on the pedicle screws. 
Moreover, the clip interface must be dimensioned so that it fits flush against the 
spinal fusion rod. 
 
2. Retain drug in reservoir for 1 week without leakage. 
The membrane must retain drug at least as long as vacuum suture drains are 
implanted, which is typically two to three days. Ideally, the drug would be 
released right after removal of suture drains when there is the minimum amount 
of bacteria in the wound space. The one-week range was chosen to demonstrate 
the range of flexibility a clinician would have in triggering release. Minimizing 
leakage is important because there would be less antibiotic to deliver during 
triggered release, attenuating the efficacy of the treatment. 
 
3. Trigger release of drug with ultrasound, achieving complete release within 24 
hours. 
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The goal of the antibiotic therapy is to deliver a supratherapeutic surge of 
antibiotic directly to the wound site to kill all bacteria. Therefore, the goal is a 
triggered quick and complete release. Incomplete release may result in extended 
subtherepeutic levels of antibiotic, which may give rise to antibiotic resistant 
bacteria. 
 
2.5 Comparative Decision Matrix 
 
Three local antibiotic delivery methods were compared on multiple criteria. Numbers in 
the matrix represent a ranking: 1 is the worst ranking while 3 is the best. Active drug 
release coatings are currently under investigation to deliver antibiotics directly to the 
surgical site during the peri-operative period. Surgical site injection is an injection of 
antibiotic directly to the wound site following removal of suture drains. 
 
 
Table 1: Comparative matrix ranking three local antibiotic administration methods on key 
criteria. Often the ranking is tied between two approaches, thus two approaches will be 
granted the same score. 
 
Criteria PEEK Clip Active Coating Surgical Site Injection 
1. Least invasive 2 2 1 
2. Min. loss from  drains 2 1 2 
3. Min. human error 2 2 1 
4. Min. surgical damage 2 1 2 
5. Synergy with other tech 3 1 2 
6. Min. long term effects 1 2 2 
7. Enhanced by US 3 1 1 
    
Total 15 10 11 
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1. The SLS PEEK Clip and active coating are both equally invasive as they are both 
implemented in a minor step during implantation surgery. Injection is more 
invasive since it will introduce a foreign object with the potential for skin 
contamination and cause tissue disruption to an already painful surgical site. 
2. Because the clip and the injection would both administer antibiotic after removal 
of vacuum suture drains, they both equally minimize antibiotic loss. Active 
coatings lack temporal control, thus release will begin at the time of surgery and 
antibiotic will be lost to suture drains attenuating antibiotic therapy.  
3. Surgical site injection has the largest propensity for human error since an injection 
to one area of the surgical site will not ensure coverage over the entire device. In 
fact, there would be no way of knowing if the antibiotic even made it to the 
implant where it would be most effective at eradicating adherent bacteria. The 
clip and the antibiotic coating both require minimal implementation on the part of 
the surgeon and both have a low propensity for human error.  
4. A major disadvantage of any antibiotic coating is that it may be damaged during 
surgery through scratching or shearing. The clip is attached after instrumentation 
has been implanted, thus it is unlikely that it would sustain any surgical damage 
that would impair its function. Injection would occur long after surgery so it has 
no potential for surgical damage. 
5. The biggest advantage of the clip is that it will work in synergy with other 
antibiotic prophylaxis. The clip could be used in synergy with a passive 
antimicrobial coating, delivering antibiotic peri-operatively, while the coating 
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could remain to prevent attachment of bacteria long-term. An active coating 
displaces the potential for any long-term passive coating. Once it releases its drug, 
it is essentially useless. 
6. An undeniable disadvantage of the clip is that, after release of antibiotic, it 
remains attached to the implant. Active coatings do as well, however, they do not 
add as much bulk to an instrumented spinal fusion system as the clip. Moreover, 
injection does not entail any implantation, thus, there would be no long-term 
effects from an injection. 
7. Recent revelations about biofilm-disrupting effects of ultrasound have shown 
great clinical promise. However, there is currently no method for delivering 
antibiotics to the surgical site in tandem with biofilm. The antibiotic released from 
the clip would have an enhanced effect on biofilm because of the administration 
of ultrasound, making this therapy superior to active release coatings and surgical 
site injections. 
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3. SPECIFIC AIM 1: Manufacture and Verify Clip 
 
 
3.1 Aim Description and Hypothesis 
 
The clip will be manufactured in selective laser sintered poly(ether ether ketone) (SLS 
PEEK). This manufacturing process takes an input CAD file and builds a solid part, layer 
by layer, that is (in theory) an exact replica of the input file. To ensure the clip is 
accurately manufactured, critical dimensions of the clip will be measured using micro 
computer cosmography (μCT). SLS is known for producing porous materials. Because 
this could potentially present another path of escape for drug within the reservoir, 
porosity will also be assessed using μCT. The two hypotheses of this aim are: 
 
1. There will be no significant difference between the dimensions of the CAD 
drawing and the dimensions of the SLS PEEK clip. 
2. The SLS PEEK Material will be porous. 
 
3.2 Polyetheretherketone (PEEK) 
 
PEEK is a hydrophobic polymer with a precedent of success in the spine. PEEK spinal 
fusion rods are gaining popularity as semi-rigid instrumentation, which allow for a 
greater range of motion and better stress distribution than stainless steel rods [40]. 
Anterior lumbar fusion cages made of PEEK have also been used to promote fusion while 
restoring disc height and providing perioperative stability [41]. There are a few key 
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properties that make PEEK an excellent material for implantable medical devices. With a 
glass transition temperature of 143 oC, the polymer behaves like a crystalline solid at 
body temperature, conferring an elastic modulus between 3 and 4 GPa [42]. Its melting 
temperature is 343oC, meaning PEEK can be autoclaved repeatedly with virtually no 
effect on the surface or bulk properties [42]. It is also chemically stable, and does not 
succumb to conventional modes of polymer degradation such as hydrolysis [43]. 
 
3.3 Selective Laser Sintering 
 
Currently the only clinical use of PEEK implants manufactured via Selective Laser 
Sintering (SLS) is in treating craniofacial defects [44]. SLS PEEK is optimal for this 
application because patient-specific cranial implants can be rapidly manufactured within 
a matter of days. Three dimensional computer-aided design (CAD) files are input into the 
SLS machine to specify the dimensions and shape of the part [45]. A thin layer of PEEK 
powder, 100-200 μm thick, is spread across a plate and heated to just below the polymer 
melting point. Orchestrated by the beam deflection system, a laser is applied to the 
powder, melting the PEEK and allowing them to flow together. After cooling, a single 
solid cross section of the part is generated while particles on the plate that have not been 
sintered remain as loose powder. Then another thin layer of powder is spread and the 
process repeats, creating a 3-dimensional construct that is an agglomeration of many 
layers of melted and re-solidified polymer. 
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Like many other additive manufacturing techniques such as 3-dimensional printing, there 
is an inherent porosity to the material. In the case of SLS, this is due to incomplete 
particle fusion, where the particles in their molten state do not completely fuse together to 
form a solid construct (Figure 6). 
 
 
Figure 6: Individual particles are distributed in a thin layer and heated to just below 
melting temperature. After application of the laser, molten particles fuse together to form 
a solid construct, however, particle fusion is often incomplete, resulting in a porous 
material. 
 
 
 
 
SLS manufacturing parameters can be altered to minimize material porosity. For 
instance, particle morphology plays a large role in material porosity. Irregularly shaped 
particles with sharp angles and “flaky” edges will not flow together as well during 
sintering, leading to more porosity [46]. Porosity is also inversely proportional to laser 
energy density, indicating that more particle flow is achieved when more energy is 
applied [47]. 
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3.4 Design and Manufacturing 
 
To design a clip that properly attaches to a standard 5.5 mm spinal fusion rod and does 
not impinge on pedicle screw placement, key dimensions were measured from a tri-level 
spinal fusion rod retrieval (courtesy of the Implant Research Center, Drexel University, 
Philadelphia, PA). Because the pedicle screws interface very tightly with the fusion rod, 
marks can be observed on the surface (figure 7).  
 
 
Figure 7: (A) Tri-level spinal fusion rod retrieval has clear notches indicating where the 
pedicle screws interface with the rod. The distance between notches (B) was measured as 
12 mm. The height of the clip was designed to allow 1.5 mm of clearance on each side so 
the pedicle screws do not impinge on the clip. 
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The distance between these marks was 12.00 mm, which was taken as the amount of 
room on the rod for the clip. The final clip height was 3 mm shorter than this distance to 
allow plenty of space between the pedicle screws and the clip. The clip was designed in 
Solidworks 2014. STereoLithography (.STL) files were sent to the Centre for Additive 
Layer Manufacturing at University of Exeter (Exeter, UK) and manufactured in SLS 
PEEK. Upon receipt from Exeter University, clipping action was qualitatively assessed 
using a standard 5.5 mm spinal fusion rod retrieval (Figure 8). 
 
 
 
Figure 8: Clips attach to the 5.5 mm spinal fusion rod with moderate force and fit flush 
against the rod. 
 
 
 
The clipping test revealed that moderate force was required to attach the device to the 
rod. Once attached, the clip fits flush against the rod and does not slide down the rod. 
Accuracy of six critical dimensions on four clips was assessed via Scanco μCT 80 (0.01 
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voxel resolution). They were the width and height of the cylindrical clip, the thickness of 
the wall, the horizontal and vertical diameters of the drug delivery channel, and the 
diameter of the clip interface (Figure 9). Four clips were scanned and measured to ensure 
repeatability of manufacturing. Measurements revealed no significant difference between 
any of the measured and designed dimensions when compared via a student’s t-test 
(α<0.05).  
 
Figure 9 (From left to right): Frontal, isometric, and top view of Solidworks drawings of 
the clip. Six critical dimensions were measured via μCT. 
 
 
Figure 10: Comparison of designed and measured clip dimensions of four devices reveals 
no significant difference. 
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3.5 Porosity Analysis 
 
One clip underwent μCT porosity analysis, which revealed 38% porosity and an average 
pore size of 0.23 mm.  
 
 
 
Figure 11: (A) Cross-section of a µCT rendering reveals pores distributed throughout the 
material. (B) Histogram of pore size distribution normalized to total porous space. 
 
 
The clips were also imaged using scanning electron microscopy (SEM) with an electron 
beam voltage of 5 kV at a working distance of 18.44 mm. Prior to imaging the surface 
was sputter coated with platinum (40 mA current, 40 seconds). The high magnification 
image (500 x) shows sintered PEEK particles on the surface of the clip ranging from 1 
μm to 100 μm. The low magnification image (120 x) illustrates the bulk appearance of 
the material. Large voids were observed between the particles, supporting the findings of 
the μCT study. 
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Figure 12: SEM Images of the material surface. (top) 500 x image shows individual 
particles ranging from 1 to 100 μm that are only partially sintered. (bottom) 120 x image 
shows voids throughout the un-fused particles. 
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3.6 Discussion 
 
This assessment demonstrated that SLS was an effective technique for manufacturing the 
drug delivery clip. Hypothesis 1 was supported, in that there were no significant 
differences between the Solidworks design and the physical clip (Figure 10). This 
analysis was performed on four clips demonstrating that the manufacturing technique was 
repeatable. The clip also fits flush against a spinal fusion rod retrieval, showing resistance 
to longitudinal sliding. Although not quantitatively assessed, the clip attached to the 
spinal fusion rod retrieval with moderate force. Ease of clipping gives the rod good 
clinical translatability as the device will not prolong procedure time. Moreover, surgeons 
will have to undergo minimal training to use this device. 
 
As is the case for all materials made through additive manufacturing techniques, SLS 
PEEK is inherently porous, supporting hypothesis 2. This is primarily due to incomplete 
particle fusion in which the particles do not completely flow together during laser 
sintering, seen in the SEM images (figure 12). As seen in the cross section of figure 11, 
pores are homogenously dispersed throughout the material and are an average size of 
0.23 mm. The SEM images further illustrate the incomplete particle fusion, as individual 
PEEK particles are clearly visible on the material surface. It is almost certain that release 
will proceed through the voids between these un-fused particles, therefore, this release 
will have to be taken into account during model development in aim 2.  
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4. SPECIFIC AIM 2: Model Release Rate and Validate 
 
4.1 Aim Description and Hypothesis 
 
Before applying a membrane, it is important to determine how fast drug will release from 
an uncoated clip. The addition of a membrane will slow release, therefore, the rate 
determined here will be the fastest possible. Since the clip was found to be 38% porous in 
aim 1, it is also important to assess any leakage out of the porous walls. If leakage does 
occur from the walls, it will motivate the application of a membrane around the entire 
clip instead of simply sealing the drug delivery channel. The hypothesis of this aim is: 
 
1. Release from the clip can be accurately modeled using a steady state dissolution-
diffusion model. 
 
4.2 Model Development 
 
The model developed uses Noyes-Whitney principles to consider the dissolution of solid 
drug and Fick’s laws to consider diffusion out of the device. Two modes of drug release 
are analyzed: out of the drug-delivery channel and out of the porous walls of the SLS 
PEEK material. 
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4.2.1 Release from Drug Delivery Channel 
 
                               
Figure 13: Release through the drug delivery channel is constant. Concentration within 
the clip is constant as drug is constantly dissolving, while outside of the clip is an infinite 
sink (drug concentration is 0). 
 
  
When drug releases through the delivery channel, it diffuses down a linear 
concentration gradient according to Fick’s law of diffusion. 𝑁 = 𝐷 !"!"     (equation 1.1) 
Where N is the molar flux and D is the diffusion coefficient. Because drug is 
constantly dissolving within the reservoir, we consider the concentration (c) of 
drug within the reservoir constant and equal to the solubility of methylene blue, 
CS. We also consider the media around the clip to be an infinite sink in which the 
concentration of drug is zero. This is because in vivo, the antibiotic will quickly 
be swept away from the clip by the vascular system. Finally, the distance between 
the source and sink is equal to the thickness of the clip wall, x. 
	   	   	   	   	  
	  
28
𝑁 = 𝐷 (!!!!!)!        (Equation 1.2) 
Molar flux is the flow of moles per second per unit surface area (mol/s-m2), 
therefore, it must be multiplied by the cross-sectional area of the flow path. In this 
case, it is the circular cross-sectional area of the drug delivery channel, ACHAN. It 
is also divided by the initial mass of drug loaded, Mo, to achieve a normalized 
release rate in terms of percent release (dQCHAN/dt). !!!"#$!" = 𝑁 !!"#$!!        (Equation 1.3) 
Combining equations 1.2 and 1.3, we arrive at a final equation describing percent 
release rate. !!!"#$!" = 𝐷 !!"#!!! (!!!!!)!        (Equation 1.4) 
 
5.3.2    Release from Porous Walls 
 
               
Figure 14: Release through the porous walls is constant. Concentration within the clip is 
constant as drug is constantly dissolving, while outside of the clip is an infinite sink (drug 
concentration is 0). 
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Release from the porous walls of the clip is similar to the previous model in that 
concentration of drug inside the reservoir is CS and the concentration outside is 0. 
However, the geometry of the diffusion path in this case is cylindrical instead of 
linear. Using these two assumptions, we can apply a steady state Fickian diffusion 
model considering radial diffusion. 0 = −𝐷 !! !!" 𝑟 !"!"        (Equation 2.1) 
To analytically solve this equation, a set of 
boundary conditions must be applied. 
Considering the clip as a hollow cylinder, we 
define two radii: the inner radius within the 
clip wall, Ri, and the outer radius outside the 
clip wall, Ro (Figure 15). During release, we 
assume that the concentration at Ri is equal to 
the solubility of drug, CS, while the 
concentration at Ro is zero. Applying these 
conditions allows integration of equation 2.1. !"!" = !!!∙!"   !! !!        (Equation 2.2) 
Equation 2.2 essentially describes the radial concentration gradient. This can be 
plugged into Fick’s first law, which relates molar flux, N, to the concentration 
gradient by the diffusion coefficient. 𝑁 = −𝐷 !"!"       (Equation 2.3) 
Figure 15: Boundary conditions 
used to analytically solve 
Equation 2.1. 
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𝑁 = − !! !!!"   !! !!        (Equation 2.4) 
As in the previous case, molar flux is per unit surface area, therefore, it must be 
multiplied by cylindrical surface area of the clip, ACYL. It is then normalized to the 
initial mass of loaded drug to achieve percent release. !!!"#!" = !!∙!! !!∙!!"#!" !! !!        (Equation 2.5) 
A final consideration of the model is that the drug is diffusing through a porous 
material, therefore, release rate will be slower relative to diffusion through a pure 
liquid medium. Two unit-less terms are introduced that correct for this: percent 
porosity, ε, and tortuosity, τ.  𝐷!"" = −𝐷! !!       (Equation 2.6) 
Where DO is the diffusion coefficient of the drug in a pure liquid medium and DEff 
is the corrected diffusion coefficient [48, 49]. ε was measured using μCT (see 
section 5.2), while τ is an empirically-derived constant. For a packing of spherical 
pores, τ is approximately 3 [48, 49]. Combining equations 2.5 and 2.6, the final 
equation for percent release from the porous cylindrical walls of the clip is: !!!"#!" = !!!!∙!∙!! !!∙!!"#!" !! !!        (Equation 2.7) 
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5.3.3    Combining Release Modes 
 
Because drug will release from the clip both through the porous walls and through 
the drug release channel, the true release rate is the sum of both of these rates. !!!!" = !!!"#$!" + !!!"#!"       (Equation 3.1) 
Thus, a final percent release rate can be determined by combining equations 1.4 
and 2.7 into 3.1. !!!!" = 𝐷! !!"#$!! (!!!!!)! + !!!!!∙!∙!! !!∙!!"#!" !! !!        (Equation 3.2) 
 
4.3 Model Validation Release Experiment 
 
To validate the model, a drug release experiment was performed. Approximately 120 g of 
powdered methylene blue (MeB) was loaded into two clips. MeB was selected as the 
simulated drug because it is well characterized in the literature and has solubility 
properties similar to our target antibiotics. Both clips were submerged in 200 mL of PBS 
at 37o C under moderate shaking (90 rpms). Media was refreshed every 30 minutes and a 
small aliquot was collected for analysis. Aliquots were plated on a flat-bottom 96-well 
plate and scanned in a TECAN Infinite® M1000 spectrophotometer (λ=600 nm). 
Concentrations were measured against a standard curve (R2>0.99). Release data was fit to 
a linear regression and the slope of the regression line was plugged into the model 
(equation 3.2) to back-calculate the diffusion coefficient, DO. 
 
	   	   	   	   	  
	  
32
4.4 Results 
 
Release experiment was performed in duplicate and the data was fit to a linear regression, 
which revealed 3.27% release per hour over the first three hours (R2=0.996).  
 
 
 
Figure 16: Release results were fit to a linear regression (R2=0.996), revealing a 3.27% 
release rate over the first 3 hours. 
 
 
This percent release rate was plugged into equation 3.2 of the model along with 
parameters from the Solidworks design (ACHAN, MO, x, ACYL, RO, Ri) and the porosity of 
the SLS PEEK material (ε, measured via μCT). The solubility of methylene blue in water 
was found from the literature [50] and the tortuosity factor (τ) was approximated as that 
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of a sphere pack [48, 49]. The equation was then used to calculate the diffusion 
coefficient (Do) of methylene blue in water. 
 
 
 
 
 
Table 2: Parameters used in the mathematical model validation. 
 Parameter Description Value 
Experimental dQT/dt Release Rate 3.27% /h 
 
Solidworks ACHAN Cross-Sectional Area of Channel 7 mm2  
 ACYL Cylindrical Surface Area of Clip 339 mm2 
 x Wall Thickness 1.5 mm 
 RO Outer Radius of Clip 6 mm 
 Ri Inner Radius of Clip 4.5 mm 
 MO Initial Mass of Loaded Drug 120 mg 
    
μCT ε Porosity 0.38 
    
Literature CS Solubility of MeB in Water 4.36×107 mg/m3 
 τ Tortuosity Factor 3 
    
 
 
Ultimately, a diffusion coefficient of 7.16×10-8 m2/s was calculated. However, looking at 
the release profile extended over ten hours, release rate accelerates at 3 hours and 
diverges from the model (figure 17).  
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Figure 17: Release profile extended over 10 hours shows divergence from model at 3 
hours. 
 
 
This accelerated release proceeds from hour 3 to 5, then release slows again and 
asymptotically reaches 98% release by 10 hours. 
 
4.5 Discussion 
 
The final model (Equation 3.2) predicts a linear release profile governed by dimensions 
of the clip, physical properties of the loaded drug, and properties of the porous SLS 
PEEK material. Release over the first three hours fit very well to a linear regression 
(R2=0.996), which showed a release rate of 3.27 % per hour (Figure 16). This was used to 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 2 4 6 8 10 
Pe
rc
en
t	  R
el
ea
se
	  (%
)	  
Time (h) 
Experimental 
Linear Fit 
	   	   	   	   	  
	  
35
back-calculate the diffusion coefficient for MeB, 7.16×10-8 m2/s, which is within the 
same order of magnitude as reported diffusion coefficients for MeB in water. Agreed 
upon values for diffusion of MeB range from 5.5 x 10-8 m2/s to 0.5 x 10-9 depending on 
experimental conditions [51, 52, 53].  
 
 
Table 3: Previously-determined values of the diffusion coefficient of methylene blue. 
D (m2/s) Temperature (oC) Source 
5.05 x 10-8 32 Vadievelan et. al 
1.34 x 10-9 30  Sakar et. al 
0.83 x 10-9 25 Leasit et. al 
   
 
 
The diffusion coefficient I have derived is slightly higher than values reported in the 
literature, most likely because of my experimental conditions. First, moderate shaking 
during incubation introduced a small amount of convection, which would accelerate 
dissolution and release. This was employed to better simulate sink conditions experienced 
in vivo, in which drug would be immediately transferred away from the clip via the 
vascular system. Moreover, all of these diffusion coefficients were found at temperatures 
lower than 37o C, which was the temperature at which my release experiment was 
performed to simulate body conditions. Increased temperature is known to accelerate 
diffusion, which would lead to a higher diffusion coefficient. Despite these slight 
differences in experimental conditions, the diffusion coefficient derived here is 
comparable to literature values, adding support to the validity of the model. 
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This model is initial evidence that release occurs through the porous walls of the clip and 
the drug release channel. For reference, when performing the same back calculation for 
Do using equation 1.4, which assumes release only occurs through the drug delivery 
channel, Do is equal to 5.36 x 10-7 m2/s. This Do is one to two orders of magnitude from 
the literature values for diffusion of methylene blue through an aqueous medium, which 
is added evidence that this is not the only drug-delivery route. However, this initial 
validation needs to be followed up with a few more release experiments to confirm 
validity. To further validate the model, one could test release out of the same clip design, 
made from a variety of porous PEEKs and a completely non-porous PEEK. What I would 
expect to see is a correlation between release rate and percent porosity since they are 
positively correlated according to the model. I would expect the non-porous material fit 
best to equation 1.4.  
 
At three hours release accelerates, diverging from the linear model (figure 17). If the 
model accurately describes release for the first three hours, what changes at hour three to 
accelerate release? Examining the parameters in Table 2, it is unlikely that the solubility 
of MeB (a physical property of the molecule) changes over time. Likewise, the pore 
structure of the SLS PEEK material and the dimensions of the clip are unlikely to change 
since PEEK does not swell. Thus porosity, tortuosity and the clip dimensions probably do 
not vary over time. 
 
My current hypothesis is that the solute-solvent surface area (ACHAN and ACYL) changes at 
hour three due to particle dispersion. An assumption of the model is that the MeB powder 
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is well packed within the reservoir, behaving like one solid instead of an aggregation of 
particles. This allowed us to approximate the solute-solvent surface area as the cross-
sectional area of the drug delivery channel and the cylindrical surface area of the clip. 
However, if particles disperse, the solute-solvent surface area drastically increases. 
Because release rate is proportional to the solute-solvent interface, when particles 
disperse, release rate increases. 
 
This accelerated release was observed from 3 to 5 hours, then release slows once again. 
At this point, the particles within the bulk of the reservoir that were not as densely packed 
have probably all been depleted. The release from hours 5 to 10 is probably from 
particles that are stuck against the sides of the reservoir wall, which would be more 
compact and less prone to dispersion. This segment of the release profile is also non-
linear as MeB depletes and release asymptotically approaches 98% at 10 hours. 
 
Despite these limitations, a key take away of the model is that release does proceed from 
the porous walls. Porosity analysis in specific aim 1 (Figure 11) revealed spherical pores 
distributed through the SLS PEEK material. It was important to characterize porosity as 
equation 3.2 of the model shows that release rate is governed by percent porosity (ε) and 
tortuosity factor (τ). 
 
Percent porosity is merely the percent of the volume that is empty space within a given 
volume (in this case the volume of the clip). Tortuosity, is less tangible as it is an 
empirically-derived correction factor. While tortuosity in two dimensions is defined as 
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the ratio of length to curvature of a channel, translating that definition to three 
dimensions becomes difficult to measure. Instead of attempting some sort of physical 
measurement, tortuosity of 3-dimensional pore networks has been empirically derived by 
back-calculating the diffusion coefficients from release experiments through porous 
materials [54]. The major finding from these experiments is that materials of comparable 
percent porosity will exhibit different release rates based on the geometry of their pores 
[54]. To correct the diffusion coefficient for these changes, the tortuosity factor is 
applied. For example, a network of spherical pores has a τ of 3, but a cylindrical network 
(such as a capillary bed) has a τ between 1.14 and 1.5 [55]. The SLS PEEK pores were 
assumed to be of a spherical geometry based on cross-sectional images (Figure 11 (A)). 
 
The other major conclusion from this experiment is that release will occur over 10 hours 
for an uncoated clip. The application of any membrane will inherently obstruct the 
diffusion path and slow release. We want complete release within 24 hours of sonication, 
therefore, this experiment shows that the membrane cannot prolong release more than 14 
hours. 
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5. SPECIFIC AIM 3: Membrane Development 
 
 
5.1 Aim Description and Hypotheses 
 
The membrane must serve two, seemingly conflicting, functions. It must be thick enough 
to retain drug within the reservoir for 7 days post-operatively but must be thin enough to 
release the drug when ultrasound is applied. I hypothesize that: 
1. The membrane thickness can be varied. 
2. The optimal membrane thickness can be achieved, which holds drug for 1 week, 
but ruptures in response to ultrasound. 
 
5.2 Ultrasound-Triggered Drug Delivery 
 
Ultrasound (US)-triggered drug delivery is currently being investigated for a wide variety 
of treatments, including cancer chemotherapy, gene delivery, and as a way of bypassing 
the blood brain barrier. In general, all US-triggered drug delivery involves a hydrophobic 
drug carrier encapsulating a payload of drug and a small volume of air. When submerged 
in an aqueous medium, this carrier exists at a constant volume. However, the application 
of US to the medium induces pressure oscillations, which cause the bubble to expand and 
contract in a process known as cavitation [56]. If the amplitude of the pressure 
oscillations surpasses the cavitation threshold, the carrier will expand and then implode, 
causing the bubble to fragment and the encapsulated drug to escape [57]. 
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Current popular drug carriers include PLA and PLGA microspheres, micelles, and 
lipospheres, which range from nanometers to micrometers in diameter [58]. Traditionally, 
large quantities of these carriers are administered via intravenous infusion. Local drug 
delivery is achieved at the site of sonication, where bubbles in the area are cavitated; 
bubbles that are not exposed to US remain intact and are excreted through the renal 
system [59]. 
 
It has also been recently demonstrated that US can increase the permeability of a 
membrane. This is currently being investigated as a method for bypassing the blood brain 
barrier, by temporarily increasing permeability of the brain’s endothelial cells [56]. In an 
in vitro study, a monolayer of endothelial cells were exposed to lipid microbubbles and 
sonicated at an amplitude of 500 kPa and frequency of 1.5 MHz for 5 s  [60]. Although 
the physical mechanism is not fully understood, it appears that the expansion of the 
microbubbles near cell membrane surface temporarily displaces the plasma membrane, 
allowing endocytosis of microbubbles [56]. Cells exposed to ultrasound experienced 
significantly more permeability to a dye for up to 3 hours relative to unsonicated controls 
[60].  
 
5.3 Alternative Triggered Drug Delivery Techniques 
 
Drug delivery triggers can be divided into two major categories: externally-applied 
triggers, and local environment triggers. Ultrasound is an example of an external trigger 
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which can be applied by the physician, thus affording the clinician precise temporal 
control over drug release. Another external trigger is heat, which is being investigated to 
release chlohexidine from styrene and n-butyl(meth)acrylate co-polymer films [61]. At 
48o C this polymer releases the antibiotic in a burst, much like the ultrasound release clip, 
and could be applied as a surface coating, mitigating the need for the clip attachment. 
However, heating the local tissue to 48 o C for more than 20 seconds caused tissue 
damage. Near infrared (NIR) triggered photodegradable polymers can also be applied to 
surfaces [62]. This coating can actually be applied using layer-by-layer assembly 
(dipping) which is a similar technique used here to apply the PLA membrane. The NIR 
trigger is not cytotoxic and the thickness and morphology of the coating can be tuned. 
The photodegradation technology also rely on the presence of heavy metals such gold 
and silver, which have their own antimicrobial effects. 
 
Local environment schemes rely on changes to the local tissue environment to trigger 
drug release. These drug carriers can be considered self-defensive since they respond to 
local bacterial activity to trigger release. Polymeric cross-linkers have been designed, 
which degrade in responsive to changes in local pH caused by bacterial activity [63]. 
These can be small microsphere carriers or layer-by-layer film deposits on polymeric 
substrates [64]. These films show remarkable stability, retaining antibiotic for many 
months post-implantation and, therefore, are a long term option in managing local 
infection. However, an area of concern with these approaches is that by the time bacteria 
proliferate enough to trigger release, the biofilm may have already developed antibiotic 
recalcitrance. 
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A final drug-delivery method that merits review here is degradation-controlled drug 
delivery. Theoretically, a membrane could be designed with the same retention function 
that has been laid out here. However, instead of release being triggered with ultrasound, 
the membrane could erode at the water-membrane surface until releasing drug at one 
week. This degradation-controlled system would require a hydrophobic polymer that 
undergoes surface erosion such as polyhydroxyalkanoates, polyanhydrides, or polyacetals 
[65]. This approach lacks the external ultrasound trigger, however, which would also 
disrupt the biofilm and increase its antibiotic susceptibility. Moreover, many of the 
degradative byproducts of these polymers are inflammatory, which may prolong wound 
healing. 
 
5.4 Poly(lactic acid) 
 
Poly(lactic acid) (PLA) is commonly employed in drug delivery applications such as 
microspheres [66]. Its extreme hydrophobicity is often used to delay drug release, 
preventing the encapsulated drug from mixing with the aqueous environment of the body. 
Release from PLA is often degradation-controlled, as PLA readily undergoes hydrolytic 
degradation [67]. This involves bulk erosion, in which, ester bonds throughout the 
polymer backbone undergo chain scission [67]. Relative to other popular drug carrying 
polymers PLA degrades very slowly, showing 90% retention in vivo over 15 weeks [68]. 
PLA’s slow degradation is ideal for the drug delivery clip, which relies on a solid 
hydrophobic membrane for 1 week. The primary byproduct of degradation is lactic acid, 
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which is naturally produced by human cells during anaerobic respiration. However, the 
build up of lactic acid in vivo has been shown to cause chronic inflammation [68]. 
 
5.5 Membrane Development 
 
Clips were loaded with approximately 120 mg of MeB and PLA (75-120 kDa) 
membranes were applied via submersion in PLA-chloroform (CHCl3) solutions. All clips 
were submerged in a PLA-CHCl3 and dried for 10 minutes in between coatings. One 
group of clips, was coated 5 times in a PLA-CHCl3 solution of 50 mg/mL (5-50 group). 
Another set of clips were submerged ten times in 50 mg/mL solution (10-50 group). A 
final set of clips was submerged five times in a PLA-CHCl3 concentration of 250 mg/mL 
(5-250). After coating, all clips were left out over night to ensure complete solvent 
evaporation. 
 
Two batches of clips were made. In batch one, two of each clip was manufactured. In 
batch two, three of each clip was manufactured. The only difference in manufacturing 
between the two batches was in drying method. To dry the clips of batch one, the clips 
were set on their side on the bench top (figure 18-A), which created a significant contact 
area between the clip and the bench top. 
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Figure 18: (A) Batch one clips were dried on their tops and were difficult to remove from 
the bench top after drying. (B) Batch two clips were dried on their flanges, minimizing 
interfacial area with the bench top. 
 
 
After drying, it was rather difficult to remove the clip from the bench top and significant 
force had to be applied with tweezers to remove the clip from the bench top. This may 
have disrupted the membrane and created defects that affect performance. To minimize 
membrane disruption after drying, batch two clips were dried on their flanges (Figure 18-
B) to minimize the surface of the clip in contact with the bench top. Mass of clips was 
measured before and after coating. The difference between these mass measurements 
represents the amount of PLA deposited on the clip. 
 
5.6 Membrane Retention-Release Experiment 
 
Clips were attached to 5.5 mm stainless steel rods (Grade 316-L), which is the grade of 
metal used in most spinal fusion rods. Clips and rods were then submerged in 200 mL of 
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PBS at 37o C under moderate shaking (90 rpms). Media was refreshed every 24 hours and 
an aliquot was stored for later analysis.  
 
At the end of 1 week, ultrasound was applied to the medium containing the rod and clip 
for 20 minutes using a SonixRP Scanner with an L4-9 probe (Analogic Ultrasound, 
Richmond, BC, Canada) transmitted at 5 MHz and 3 MPa (peak-to-peak) acoustic output 
pressure. Media was refreshed and collected 1, 2, 3, 6 and 24 hours after sonication. 
Aliquots were placed in a flat-bottom 96-well plate and scanned in a TECAN Infinite® 
M1000 spectrophotometer (λ=600 nm). Concentrations were measured against a standard 
curve (R2>0.99). Release profiles before and after sonication were fit linear regressions 
and percent release rates were used to compare coatings. 
 
5.7 Results 
 
Upon submersion in the PLA-CHCl3 solution, some MeB leached from the clip into the 
solution, although this mostly occurred on the first submersion. After drying for 24 hours, 
the membranes were blue indicating that some MeB was trapped within the PLA. 
However, PLA was only visible on the surface of the 5-250 clips from either batch. There 
was no visible PLA deposited on the surface of the 5-50 or 10-50 clips, however, mass 
measurements taken before and after coating indicate that 86.5 mg of PLA was present 
on or in the 5-50 clips from batch one, and only 7 mg of PLA was present on those from 
batch 2. The 10-50 clips from batch one contained 161 mg of PLA and the 5-250 clips 
had 173.5 mg of PLA. This is in contrast to the 10-50 clips from batch 2, which only had 
13 mg of PLA. Clips were imaged via SEM using the method described above in Aim 1. 
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All images were taken at 120 x to get an overview of the state of the material surface 
after coating. SEM images reveal that the 5-250 technique resulted in the thickest and 
most homogenous surface layer. In fact, the original morphology of the SLS PEEK 
material is no longer visible. 10-50 and 5-50 clips had PLA on the surface, however, 
pores were still visible throughout. All clips were attached to 5.5 mm steel rods prior to 
submersion in PBS, which simulates surgical attachment to a spinal fusion rod. 
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Figure 19: Mass measurements taken before and after coating. (Top) Measurements of 
the batch one clips show the 5-50 clips contained 80 mg of PLA, the 10-50 clips had 161 
mg and the 5-250 clips contained 173.5 mg. (Bottom) An order of magnitude less PLA 
was deposited on the 5-50 and 10-50 batch two clips. However, 80 mg more PLA was 
deposited on the surface of the 5-250 clips of batch two than batch one. 
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Figure 20: (Top) SEM image of the un-coated SLS PEEK material. (Bottom) The surface 
of the material coated with the 5-50 technique. PLA is deposited on the surface and 
within the pores, although pores are still visible. 
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Figure 21: (Top) Surface of the 10-50 shows even more PLA deposition than the 5-50 
technique, although pores are still visible through (Bottom) The 5-250 membrane is a 
thick layer that completely hides the original morphology of the SLS PEEK surface. 
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During the incubation period (up to day 7) of the batch one clips, the 5-250 clip leaked 
the least with only 19% of the MeB releasing. The 5-50 and 10-50 clips both allowed 
38% release during the first week. All of these release profiles are seemingly linear. 
 
 
 
Figure 22: The 5-250 clips allowed for 19% MeB release over the first week, while 5-50 
and 10-50 clips both allowed 38% release. Ultrasound was applied at day 7 and release 
was observed for an additional 24 hours. 
 
 
 Release profiles from before and after sonication were fit to linear regressions (R2>0.59). 
5-50 and 10-50 clips had comparable release rates (5.85 and 5.4 %/day, respectively) 
while 5-250 released 3% of its MeB per day for the first 7 days of incubation. 
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Figure 23: Pre-sonication release was fastest in the 5-50 group and slowest for the 5-250 
group. Post-sonication, release was accelerated in the 5-50 and 10-50 groups. Release 
decelerated slightly in the 5-250 group. 
 
 
Sonication accelerated release in the 5-50 clips to 10.0 %/day and accelerated release of 
the 10-50 clips to 10.6 %/day. Release from the 5-250 membrane slightly decelerated 
after sonication. Batch two release profiles were non-linear, instead showing an 
asymptotic profile during the 7-day incubation period (Figure 24 (top)). Ultimately 24% 
and 16% was released from the 5-50 and 10-50 clips respectively. The 5-250 clips 
showed less than 1% release during that period. After the application of ultrasound, 2% 
additional MeB release was achieved, and less than 1% from either the 10-50 or 5-250, 
seen in Figure 24 (bottom). 
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Figure 24: (top) Batch two release profiles during the first seven days of incubation. 
(bottom) Additional release following ultrasound triggering at the end of day 7. 
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5.8 Discussion 
 
Comparing the batch 1 and batch 2 manufacturing techniques, the first apparent 
difference is the amount of PLA deposited. The batch 2 5-50 and 10-50 clips had an order 
of magnitude less PLA than the batch 1 clips (figure 19). This may be because more PLA 
dripped off of the clips during drying in the batch 2 configuration. It may also be 
indicative of more efficient CHCl4 evaporation. However, with the 5-250 clips we see the 
opposite trend, with more PLA deposited in the batch 2 process than the batch 1 process. 
No matter the explanation for these differences, these two batches highlight the 
variability of the manufacturing technique that must be minimized in future 
developments. 
 
SEM imaging revealed that the 5-50 and 10-50 clips did have PLA on the surface, 
however, these membranes were thin and incomplete, with pores still distributed across 
the surface. The 5-250 clips had a thick surface layer that completely obscured the 
original morphology of the SLS PEEK surface. Based on these observations it is clear 
that the higher concentration PLA-CHCl3 solution is more favorable for creating a 
surface membrane. This is probably because the more concentrated PLA-CHCl3 solution 
is more viscous, enabling it to remain on the clip surface instead of infiltrating into the 
reservoir. These findings support my first hypothesis, in that the membrane thickness can 
be varied by varying the concentration of the PLA solution. 
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Over the first seven days of incubation, the membranes’ ability to retain drug was tested. 
This represents the time between initial implantation and drug release. In the batch 1 
assessment, the 5-250 clips showed the least leakage during this time, permitting 19% 
drug release versus the other clips’ 38% drug release. What leakage did occur from the 5-
250 clips, it was most likely from surface defects as seen in figure 25. Defects such as 
this were probably a result of handling during coating with tweezers.  
 
 
 
Figure 25: Defect observed on the surface of the 5-250 clip was probably the result of 
handling during and directly after coating. 
 
	   	   	   	   	  
	  
55
 
Batch two clips, on the other hand, featured asymptotic release, which stabilized by day 
7. The 5-50 clips in this batch only leaked 24% of their MeB, while the 10-50 clips only 
leaked 16%. The sustained release seen in the 5-50 and 10-50 clips is most likely due to 
MeB particles suspended in a PLA matrix due to infiltration of the 50 mg/mL PLA-
CHCl3 during coating. The 5-250 clips showed less than 1% leakage, indicating complete 
encapsulation of the reservoir. This indicates that the batch 2 drying configuration 
produced more complete membranes with less defects than the batch 1 clips. 
 
A modest increase in release rate was observed post sonication from the 5-50 and 10-50 
clips in batch 1. However, this may be the result of an increase in sampling rate during 
the post-sonication period. Every time media was sampled, the entire beaker was emptied 
and refilled with fresh PBS, which introduces some convection, possibly increasing 
dissolution and diffusion of the MeB. The increase in release rate may have been a result 
of this phenomena and not ultrasound. To test this, a control experiment should be done, 
to see if the accelerated release rate is observed in unsonicated clips sampled at the same 
rate. Application of ultrasound at the end of the incubation period had virtually no effect 
on release rate from any of the batch 2 clips, indicating that the membranes are too thick 
to rupture through cavitation (figure 24-bottom). Because these membranes are probably 
more complete than the batch 1 membranes, this is probably the more important finding 
to consider. Ultimately the 5-250 membrane fulfilled the retention function, more work 
needs to be done to achieve US-triggered release. 
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6 CONCLUSIONS and FUTURE WORK 
 
To date, this is the first study using SLS PEEK as a drug delivery device. As 
demonstrated by the model, the SLS PEEK is porous enough to permit diffusion. In 
future iterations of the clip, it would be favorable to minimize material porosity so that 
release only occurs through the designed drug delivery channel. This would make the 
membrane easier to apply because it would only need to seal the drug delivery channel 
and not the entire clip. Porosity of SLS material is largely determined by particle fusion 
during sintering: circular smooth particles flow together more efficiently than irregularly-
shaped particles [46]. Increasing laser energy density also makes the molten polymer less 
viscous, which promotes particle flowability as well [47]. This is an ongoing area of 
study with our collaborators at University of Exeter. 
 
A major limitation of the clip design study is that clip attachment strength was not 
quantified. Further investigation is warranted to assess clip attachment while the rod 
undergoes cyclic loading. Stainless Steel spinal fusion rods can undergo flexion during 
normal activity and are shown to fatigue under cyclic mechanical loading [69], which 
could potentially cause loosening or migration of the clip. Moreover, wear at the clip-rod 
interface could generate inflammatory wear particles. To assess loosening and wear-
particle generation, the clip could be attached to a fusion rod undergoing a cyclic loading 
test such as ASTM F1717-01. In this test, pedicle screws are drilled into polyethylene 
blocks, which simulate vertebrae, and fusion rods are loaded under physiologically 
relevant bending at 4 Hz over 2 million cycles. This test could also be done in 
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physiologically-relevant media, which could be collected and analyzed for PEEK wear 
particle generation. A method could be adapted from UHMWPE particle analysis, in 
which, particles are collected on a nuclepore filter, imaged via scanning electron 
microscopy and analyzed in ImageJ [70]. 
 
A model was derived using principles of Fickian diffusion and Noyes-Whitney 
dissolution to predict release from the clip. The model was validated over the first three 
hours of a release experiment from an un-coated clip. To confirm model validation, 
release experiments should be performed using clips manufactured in materials of various 
porosities. A positive correlation should be observed between release rate and material 
porosity, demonstrating that release proceeds faster from a more porous material. 
Moreover, release from a non-porous material should fit best to equation 1.4, which only 
takes into account release from the drug delivery channel.  
 
Assuming the model is valid, it can be used to re-design the clip. One way to accelerate 
release from the clip would be to increase the number of drug delivery channels. To 
account for this in the model, the drug release term of equation 3.2 would be multiplied 
by N number of delivery channels. The cross-sectional area of the release channel could 
also be widened to accelerate release since it is directly proportional to release rate. 
Finally, the width of the walls could be made smaller, although, this can only be 
minimized to about 1 mm, which is the minimum resolution of the SLS manufacturing 
technique.  
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Figure 26: Possible second iteration of the clip, featuring more drug delivery channels 
and a smaller clip wall. According to the model, this clip would release drug faster than 
the previous clip version. 
 
 
Figure 26 shows a second iteration of the drug delivery clip, designed with guidance from 
the model. The wall size has been minimized to 1 mm, which should provide less 
impedance for ultrasound waves to penetrate. This would also be a smaller diffusion path 
for the drug to release from. There are four, 2 mm drug delivery channels instead of one 4 
mm channel. This should better distribute drug throughout the surgical site and will 
further accelerate release. 
 
Membrane retention and release studies demonstrated a need for further membrane 
optimization to ensure the membrane can retain drug without leakage for one week and is 
also responsive to ultrasound-triggered release. One way to improve membrane retention 
is through better handling. To submerge the clips in PLA-CHCl3 solution, I had to handle 
the clips with tweezers, which could potentially disrupt the membrane. Disruption could 
be minimized with longer dry cycles between dips. This would allow the previous coating 
to solidify and decrease the likelihood of disruption with tweezers. I hypothesize that 
with better handling, the 250 mg/mL coating could completely stop leakage. Assuming 
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this could be achieved, I could then try coating clips with incrementally less concentrated 
membrane solutions, which would decrease the membrane thickness and theoretically 
increase its responsiveness to ultrasound triggered release. 
 
It is also understood that ultrasound’s ability to increase the permeability of a membrane 
is increased with the addition of microbubbles near the membrane surface. These 
microbubbles cavitate, mechanically disrupting the adjacent membrane and temporarily 
increasing its permeability. This has been used to increase the diffusivity of the blood-
brain barrier and to disrupt biofilm [36, 60]. While it would not be feasible clinically to 
inject microbubbles near the clip, it might be possible to trap more air in the membrane 
during coating. A homogenizer could be applied to the membrane solution before coating 
to make bubbles in the membrane solution, which might be retained after coating. I 
hypothesize that this entrapped air would make the membrane more responsive to 
ultrasound trigger. 
 
Another major limitation of this study is that methylene blue was used to simulate an 
actual antibiotic. Once the membrane has been optimized, the device would probably be 
loaded with a combination of vancomycin and cefazolin to kill a broad range of gram-
posotive and gram-negative bacteria. A bacterial challenge experiment could be 
performed, in which biofilm was grown on the surface of a stainless steel rod. The clip 
and rod would then be sonicated and incubated for an additional 24 hours while drug 
release proceeds. Bactericidal effect could be measured by detaching the bacteria from 
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the rod, plating and counting. This could also be compared to an unsonicated control to 
determine if there is any additional bactericidal effect using ultrasound. 
 
While there is still more work to be done to optimize the clip, this study demonstrated 
initial feasibility of an ultrasound-triggered antibiotic release clip to lumbar posterior 
fusion surgery. This device has been thoughtfully designed to fit within current clinical 
antibiotic prophyalxis, which is a multi-step system that spans the peri-operative period. 
In the context of 4-stage biofilm formation, the first line of prophylactic defense is aimed 
at preventing bacteria from attaching to the implant surface. Antibiotics are administered 
prior to the operation and surgeons follow rigorous sterile surgical techniques to 
minimize bacterial exposure. 
 
 
Figure 27: The PEEK clip will act as a tertiary defense system within the scope of 
standard clinical infection prophylaxis. It could also work in synergy with passive 
antimicrobial coatings currently under investigation. 
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While not currently in clinical use, non-fouling passive surface coatings are being 
investigated that would further prevent bacterial attachment to the implant surface. Of 
these, the most promising is silver, which inhibits a broad range of microbes and can be 
plasma sprayed onto the stainless steel fusion rods and pedicle screws. The second layer 
of defense is Vancomycin wound packing and vacuum wound closure. These have both 
shown promise at limiting infection and accelerating the formation of granulation tissue. 
 
Finally, the SLS PEEK clip offers a tertiary layer of defense. Ultrasound will play two 
roles in this system: triggering release of antibiotic, but also disrupting the bacterial 
biofilm and increasing its susceptibility to antibiotics. This technology would provide 
clinicians with a third contingency in the fight against surgical site infection. Once 
implemented, it would surely lower the incidence of surgical site infection in lumbar 
fusion surgery. 
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